Search Results 81-90 of 16503 for monoclonal antibody

  1. Alzheimer's drug lecanemab granted full approval by FDA, Mayo Clinic expert weighs in

    A monoclonal antibody, lecanemab, shows promise in removing amyloid plaques from the brain, according to phase 3 trial results. Amyloid plaques are one of ...

  2. Mayo Clinic Proceedings: In the Limelight, February 2022

    Interrupting the Progression of COVID-19 by Anti-Spike Monoclonal Antibodies: Outcomes in Two Eras ... Eligibility for anti-spike monoclonal antibody therapy ...

  3. History of COVID-19: Outbreaks and vaccine timeline

    Mayo Clinic researchers study and develop a COVID-19 diagnostic test, an antibody test, monoclonal antibody medications, convalescent plasma therapy and ...

  4. Publications - Mike M. Bierle, M.D. - Mayo Clinic

    ... Monoclonal Antibody Screening Score. Mayo Clin Proc Innov Qual Outcomes. 2023 Apr; 7 (2):109-121 Epub 2023 Jan 11. View PubMed; Yang J, Shin KM, Do A, Bierle ...

  5. Hodgkin Clinical Trials - Mayo Clinic Research

    Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a combining ...

  6. Eculizumab-aagh (intravenous route) - Mayo Clinic

    Eculizumab-aagh injection is a monoclonal antibody that works on the immune system. This medicine is available only under a restricted distribution program ...

  7. Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery - Mayo Clinic

    Monoclonal antibodies, such as pembrolizumab, may interfere with the ... Prior anti-cancer monoclonal antibody (mAb) =< 4 weeks prior to registration ...

  8. Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma - Mayo Clinic

    Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such ...

  9. Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma - Mayo Clinic

    GA101 is an anti-CD20 humanized and glyco-engineered monoclonal antibody. GA101 has been shown to have increased antibody-dependent cellular cytotoxicity ...

  10. A Study to Evaluate Maximizing Anti-PD-1 Therapy By Monitoring T Cell Responses In Melanoma, Lung and Other Cancer Types - Mayo Clinic

    ... monoclonal antibody, and compare them with clinical outcomes. Participation eligibility. Participant eligibility includes age, gender, type and stage of ...